306 related articles for article (PubMed ID: 27240501)
21. In vitro efficacy of the successive or staggered use of eardrops.
Kalcioglu MT; Ozturan O; Durmaz R; Aktas E
Eur Arch Otorhinolaryngol; 2006 May; 263(5):395-8. PubMed ID: 16328405
[TBL] [Abstract][Full Text] [Related]
22. The ongoing battle against multi-resistant strains: in-vitro inhibition of hospital-acquired MRSA, VRE, Pseudomonas, ESBL E. coli and Klebsiella species in the presence of plant-derived antiseptic oils.
Warnke PH; Lott AJ; Sherry E; Wiltfang J; Podschun R
J Craniomaxillofac Surg; 2013 Jun; 41(4):321-6. PubMed ID: 23199627
[TBL] [Abstract][Full Text] [Related]
23. Suprathel-antiseptic matrix: in vitro model for local antiseptic treatment?
Ryssel H; Andreas Radu C; Germann G; Kloeters O; Riedel K; Otte M; Kremer T
Adv Skin Wound Care; 2011 Feb; 24(2):64-7. PubMed ID: 21242734
[TBL] [Abstract][Full Text] [Related]
24. In vitro activity of ototopical drops against middle ear pathogens.
Ikeda K; Takasaka T
Am J Otol; 1993 Mar; 14(2):170-1. PubMed ID: 8389100
[TBL] [Abstract][Full Text] [Related]
25. Antibacterial effect of octylcyanoacrylate against methicillin-resistant Staphylococcus aureus isolates from patients with chronic suppurative otitis media.
Jang CH; Park H; Choi CH; Cho YB; Park IY
In Vivo; 2008; 22(6):763-5. PubMed ID: 19181004
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of common antiseptic solutions against clinically relevant microorganisms in biofilm.
O'Donnell JA; Wu M; Cochrane NH; Belay E; Myntti MF; James GA; Ryan SP; Seyler TM
Bone Joint J; 2021 May; 103-B(5):908-915. PubMed ID: 33934664
[TBL] [Abstract][Full Text] [Related]
27. Aerobic bacteria associated with chronic suppurative otitis media in Angola.
Uddén F; Filipe M; Reimer Å; Paul M; Matuschek E; Thegerström J; Hammerschmidt S; Pelkonen T; Riesbeck K
Infect Dis Poverty; 2018 May; 7(1):42. PubMed ID: 29720274
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo antimicrobial activity of topical ofloxacin and other ototopical agents.
Klein JO
Pediatr Infect Dis J; 2001 Jan; 20(1):102-3; discussion 120-2. PubMed ID: 11176586
[TBL] [Abstract][Full Text] [Related]
29. Emergence of ciprofloxacin-resistant pseudomonas in chronic suppurative otitis media.
Jang CH; Park SY
Clin Otolaryngol Allied Sci; 2004 Aug; 29(4):321-3. PubMed ID: 15270816
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the ototoxicity of an anti-MRSA peptide KR-12-a2.
Sung CM; Kim HC; Cho YB; Shin SY; Jang CH
Braz J Otorhinolaryngol; 2018; 84(4):441-447. PubMed ID: 28625810
[TBL] [Abstract][Full Text] [Related]
31. [The prevalence of antiseptic resistance genes (qacA/B and smr) and antibiotic resistance in clinical Staphylococcus aureus strains].
Nakipoğlu Y; Iğnak S; Gürler N; Gürler B
Mikrobiyol Bul; 2012 Apr; 46(2):180-9. PubMed ID: 22639307
[TBL] [Abstract][Full Text] [Related]
32. The antimicrobial effect of acetic acid--an alternative to common local antiseptics?
Ryssel H; Kloeters O; Germann G; Schäfer T; Wiedemann G; Oehlbauer M
Burns; 2009 Aug; 35(5):695-700. PubMed ID: 19286325
[TBL] [Abstract][Full Text] [Related]
33. Potential Ototopical Antiseptics for the Treatment of Active Chronic Otitis Media: An In Vitro Evaluation.
van Straten AF; Blokland R; Loock JW; Whitelaw A
Otol Neurotol; 2020 Sep; 41(8):e1060-e1065. PubMed ID: 32569134
[TBL] [Abstract][Full Text] [Related]
34. Cationic antimicrobial peptides: alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa.
Geitani R; Ayoub Moubareck C; Touqui L; Karam Sarkis D
BMC Microbiol; 2019 Mar; 19(1):54. PubMed ID: 30849936
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial susceptibility of microorganisms isolated from sputum culture of patients with cystic fibrosis: Methicillin-resistant Staphylococcus aureus as a serious concern.
Mazloomi Nobandegani N; Mahmoudi S; Pourakbari B; Hosseinpour Sadeghi R; Najafi Sani M; Farahmand F; Motamed F; Nabavizadeh Rafsanjani R; Mamishi S
Microb Pathog; 2016 Nov; 100():201-204. PubMed ID: 27666507
[TBL] [Abstract][Full Text] [Related]
36. Minimal inhibitory concentration of natural vinegar and of aluminium acetate-tartrate solution.
Lang U
Otol Neurotol; 2013 Jul; 34(5):795-7. PubMed ID: 23739558
[TBL] [Abstract][Full Text] [Related]
37. In vitro postantibiotic effects of tomopenem (CS-023) against Staphylococcus aureus and Pseudomonas aeruginosa.
Tomozawa T; Sugihara C; Kakuta M; Sugihara K; Koga T
J Med Microbiol; 2010 Apr; 59(Pt 4):438-441. PubMed ID: 20093378
[TBL] [Abstract][Full Text] [Related]
38. Design of Bactericidal Peptides Against Escherichia coli O157:H7, Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.
Cruz J; Rondon-Villarreal P; Torres RG; Urquiza M; Guzman F; Alvarez C; Abengozar MA; Sierra DA; Rivas L; Fernandez-Lafuente R; Ortiz CC
Med Chem; 2018; 14(7):741-752. PubMed ID: 29737262
[TBL] [Abstract][Full Text] [Related]
39. Synergistic effect of artocarpin on antibacterial activity of some antibiotics against methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli.
Septama AW; Panichayupakaranant P
Pharm Biol; 2016; 54(4):686-91. PubMed ID: 26427318
[TBL] [Abstract][Full Text] [Related]
40. In vitro antimicrobial activity of a commercial ear antiseptic containing chlorhexidine and Tris-EDTA.
Guardabassi L; Ghibaudo G; Damborg P
Vet Dermatol; 2010 Jun; 21(3):282-6. PubMed ID: 20030799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
